Multiple myeloma (MM) progresses from an avascular to a vascular phase (active MM) accompanied by a significant increase in microvessel density in the bone marrow. This article summarizes the literature concerning the specific role played by vascular endothelial growth factor (VEGF) in this process. Recent applications of antiangiogenic agents that interfere with VEGF signaling and block MM progression are also described.
Angiogenesis and tumor angiogenesis
Angiogenesis, the formation of new blood vessels from preexisting ones, takes place in various physiological and pathological conditions, such as embryonic development, wound healing, the menstrual cycle and chronic inflammation and tumors. 1, 2 The angiogenic cascade is a multistep process that includes sequential basement membrane degradation, endothelial cell migration and invasion of the surrounding extracellular matrix (ECM), endothelial cell proliferation and capillary lumen formation, while investment of the vessel wall with pericytes and subsequent inhibition of endothelial proliferation, basement membrane reconstitution and junctional complex formation stabilize the newly formed microvasculature.
Angiogenesis and the production of angiogenic factors are fundamental for tumor progression in the form of growth, invasion and metastasis. 1 Tumor angiogenesis is linked to a switch in the equilibrium between positive and negative regulators 3 and mainly depend on the release by neoplastic cells of growth factors specific for endothelial cells and able to stimulate growth of the host's blood vessels.
Vascular endothelial growth factor/vascular permeability factor
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is a major regulator of tumor-associated angiogenesis and promotes tumor growth, invasion and metastasis. 4 The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor. VEGF gene encodes for VEGF-A isoforms (VEGF-A 121-206 ) by alternative splicing that differently encodes exons 6 and 7 (Figure 1a) , where the peptides responsible for the heparin-binding capacity are located. 5 The heparin-binding domains help VEGF-A to anchor to the ECM and are involved in binding to heparin sulfate and presentation to VEGF receptors (VEGFR). 6 VEGF isoforms with higher heparin affinity are rapidly sequestrated by the heparansulfate proteoglycans located at the endothelial cell surface and in the ECM. Moreover, these proteoglycans are an extracellular storage of VEGF isoforms and enhance the interactions with their own receptors. 7 Several factors regulate VEGF expression, including interleukin (IL)-1b, 8 IL-6, 9 IL-10 and IL-13, 10 fibroblast growth factor-4 (FGF-4), 11 platelet-derived growth factor (PDGF), 12 transforming growth factor (TGF)-b, 13 insulin-like growth factor-1, 14 tumor necrosis factor (TNF)-a, 15 gonadotropins, 16 hypoxia and nitric oxide. 17, 18 VEGF expression may also be regulated by the von Hippel Landau and the p53 genes. Mutations of these two genes are associated with an increased angiogenesis and an increased VEGF expression. 19, 20 
VEGF receptors
All the VEGF isoforms share common tyrosine kinase receptors (VEGFR-1 or Flt-1, VEGFR-2 or KDR/Flk-1, VEGFR-3 or Flt-4) (Figure 1b) . 21 VEGF-A binds with high-affinity VEGFR-1 and VEGFR-2 with high affinity and plays an essential role in vasculogenesis and angiogenesis. 22 It has also been shown to induce lymphangiogenesis through VEGFR-2. VEGF-B overlaps VEGF-A activities by activating VEGFR-1. 23 VEGF-C and VEGF-D are both angiogenic via VEGFR-2 and VEGFR-3 and lymphangiogenic (primarily VEGF-D) via VEGFR-3. 24 31, 32 and retinal progenitor cells 33 (VEGFR-2), while VEGFR-3 is expressed on the surface of lymphatic endothelial cells. 34 A nonkinase receptor, neuropilin-1, initially shown to mediate guidance of neurite growth, acts as a high-affinity coreceptor and enhances the binding of VEGF-A to VEGFR-2 and is expressed on the surface of endothelial and tumor cells. 35 
VEGFR signaling pathway
VEGFR via phosphotyrosine residues located in the carboxyterminal region ( Figure 2 ) may activate a tyrosine kinase cascade involving various intracellular proteins, particularly phosphatidyl-inositol-3 0 kinase. 36 Mice expressing only the extracellular domain of VEGFR-1 develop normally, 37 suggesting that signaling through the kinase domain is dispensable for endothelial cell differentiation and angiogenesis. The signal transduction pathway involving VEGFR is mediated by focal adhesion proteins such as FAK, paxillin and cortactin, which are responsible for the stabilization of focal adhesion plaques and the reorganization of actin fibers. 38 Other different transduction pathways are also involved, such as the proteins Fyn and Yes of the Src family, Nck and SHP-1 and SHP-2 phosphatases for VEGFR-1, 39, 40 and Shc and Grb2 for VEGFR-2 and VEGFR-3. 41, 42 MAP kinases (MAPK) are the final effectors of the signal to the nucleus, where they modulate the expression of genes involved in several biological activities of endothelial cells, such as proliferation, migration and survival. 43 The three best-characterized families of MAPK are the extracellular signal regulated kinase (ERK1/2), stress-activated protein kinase-1 (SAPK1) and SAPK2/p38 kinases. Treating endothelial cells with VEGF activates both ERK1/2 and SAPK2/p38 MAPK and increases cell migration and incorporation of thymidine into DNA. 44 This increased migration and cell proliferation is completely dependent on activation of VEGFR-2, since it is totally inhibited by a VEGFR-2 blocking antibody. 45 These results are consistent with the concept that VEGFR-2 is a positive regulator of angiogenesis and that VEGFR-1 is involved in the downregulation of the VEGFR-2-mediated events.
Angiogenesis in multiple myeloma
In multiple myeloma (MM), bone marrow angiogenesis measured as microvessel density (MVD) increases with progression from gammopathy of undetermined significance (MGUS) to nonactive MM and the active MM, and is related with the plasma cell labeling index. 46, 47 MVD is five-to six-fold larger in active MM compared to nonactive MM or MGUS. 47 Assuming that MVD depends on angiogenesis, these results are consistent with the notion that angiogenesis favors expansion of the MM mass by promoting plasma cell proliferation.
Increased MVD and high bone marrow angiogenesis are an adverse prognostic factor in MM. 48, 49 CD34-positive microvessel areas in the bone marrow of patients with newly diagnosed MM correlate in a multivariate analysis with bone marrow plasma cell infiltration and b2-microglobulin. 50 Moreover, after chemotherapy, MVD decreases significantly in patients in complete or partial remission. 50 Myeloma plasma cells produce and release angiogenic factors such as FGF-2 and VEGF in their conditioned medium (CM) 47, 51 and also induce angiogenesis in vivo in the chick chorioallantoic membrane assay. 47 They secrete matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) and urokinase-type plasminogen activator 47 and cytokines recruiting inflammatory cells, such as mast cells that then induce angiogenesis through secretion of angiogenic factors in their granules. 52 All these findings indicate that myeloma plasma cells induce angiogenesis directly via the secretion of angiogenic cytokines and indirectly by induction of host inflammatory cell infiltration, and degrade the ECM with their matrix-degrading enzymes. This, in association with their interaction with the ECM proteins through the expression of adhesion molecules, 53, 54 explains their proliferation and diffusion in intra-and extramedullary sites.
Role of VEGF in progression of MM
It is likely that VEGF-A exerts autocrine effects, for example, by stimulating motility and survival on tumor cells that express VEGFR. 55, 56 VEGFR are predominant in endothelial cells surrounding or penetrating malignant tissue, but absent from vascular cells in the surrounding normal tissue. VEGF receptors signaling pathway.
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This finding suggests that VEGFR expression is induced in endothelial cells during tumor angiogenesis by VEGF secreted by tumor cells.
The paracrine role of VEGF in MM was first proposed by Dankbar et al, 58 who found that IL-6 stimulation of plasma cells purified from the marrow of MM patients resulted in an increase in VEGF secretion. Similarly, stimulation of endothelial cells and bone marrow stromal cells with VEGF induced a significant and dose-dependent increase in IL-6 secretion. IL-6 is a potent growth factor for myeloma cells and an inhibitor of plasma cell apoptosis. Elevated serum IL-6 receptor concentrations are associated with a poor prognosis in MM and used as an indicator of disease activity. 59 Other cytokines, including TNFa, have been reported to be involved in the control of VEGF production by myeloma cells. 60 Moreover, VEGF directly, or indirectly through its stimulatory activity on TNF-a and Il-b1 stimulates the activation of osteoclasts and thus contributes to the lytic lesions in MM. 61 Bellamy et al 62 and Podak et al 63, 64 reported expression of VEGFR-1 by myeloma cells by immunohistochemical and RT-PCR studies and Kumar et al 65 have revealed expression of VEGFR-1 and VEGFR-2 by both myeloma cell lines and primary myeloma cells.
Elevated serum VEGF in MM patients 51 is correlated with both increased angiogenesis in MM bone marrow and a higher plasma cell labeling index. 47, 66 Binding of MM cells to bone marrow stromal cells markedly upregulates VEGF secretion. 67 We have demonstrated that VEGF is secreted by myeloma cells and stimulates proliferation and chemotaxis in both endothelial cells (VEGFR-2 signaling) and stromal cells (VEGFR-1 signaling) . 68 Stromal cells, in turn, secrete VEGF-C and VEGF-D, which interact with plasma cells (VEGFR-3 signaling). We also noted higher VEGF expression in MM than in MGUS and showed that the increased proliferation and chemotaxis displayed by endothelial and stromal cells in response to plasma cells CM is not fully abolished by addition of VEGF antibody. 68 The secretion of other angiogenic cytokines may thus be presumed.
The data also show that VEGF also plays an important role in both autocrine and paracrine growth of MM cells.
VEGF as a potential target for antiangiogenic treatment
Ongoing studies on antiangiogenic treatment are reviewed by the National Cancer Institute (http://www.cancer.gov). There are many clinical studies on the use of antiangiogenic drugs in hematological malignancies.
The VEGF signaling pathway can be inhibited at various levels, that is, by blocking the activity of VEGF with monoclonal antibodies, 69 blocking the VEGFR with specific inhibitors 70 or interfering with the tyrosine kinases activated by the VEGF/VEGFR interaction. 71 Systemically administered antibodies to VEGF-A accumulate selectively in tumor vessels in much higher concentrations than in normal tissue. 72 These antibodies and those that block VEGF-A-R retard tumor growth and reduce tumor size in mice. [73] [74] [75] The latest antibodies selectively recognize the complex that VEGF-A forms with VEGFR-2 on vascular endothelium. 76 Preclinical studies with VEGF-neutralizing antibodies had shown that inhibition of VEGF inhibits MMP production and induction of apoptosis in cells expressing VEGFR, 77 suppresses the production of TNF-a and IL-1b in bone marrow stromal cells and inhibits leukemia colony formation in cultures of cells from patients with chronic myelomonocytic leukemia and refractory anemia with blast excess. 78 A humanized murine anti-VEGF monoclonal antibody, Bevacizumab, that recognizes all VEGF isoforms without crossreactivity with other growth factors has displayed potent antitumor activity in experimental models. 77 Some phase I and II studies with Bevacizumab alone or in association with other agents are under way in sarcomas, renal, breast and lung cancer and chronic myeloid leukemia. 79, 80 Another antiangiogenic target is the blockade of VEGFR or the tyrosine kinase proteins involved in signal transduction. Small selective nonimmunogenic synthetic molecules have shown specific activity associated with an acceptable toxicity profile and good resistance to enzyme lysis. 81 These compounds show good inhibition of VEGFR and may inhibit tumor cells expressing these targets. Inhibition of VEGFR signaling pathway can downregulate angiogenesis and its associated features in bone marrow of patients with MM.
Thalidomide and its immunomodulatory derivatives, 82 the proteasome inhibitor PS 341 83 and arsenic trioxide, 84,85 directly induce apoptosis or G1 growth arrest in drug-resistant MM cell lines and MM patient cells. They also inhibit the transcription, secretion and actions of cytokines, such as IL-6, VEGF and TNF-a. Gupta et al 67 found that both thalidomide and its analog ImiD1 (cc 4047) reduce VEGF and IL-6 secretion in cocultures of bone marrow stromal cells and MM cells. Finally, the postulated mechanism of action of 2-methoxyestradiol in MM includes downregulation of VEGF expression.
Lin et al 86 investigated the effect of PTK 787, a tyrosine kinase inhibitor, initially designed to inhibit VEGF signal transduction by binding directly to the ATP-binding sites of VEGFR, both directly on MM cells and in the bone marrow. They found that PTK 787 directly inhibits proliferation and migration of MM cell lines and patient MM cells that express VEGFR-1. It enhances the anti-MM activity of dexamethasone, overcomes the protective effect of IL-6 against dexamethasone-induced MM cell apoptosis and inhibits the secretion of IL-6 induced by binding of MM cells to bone marrow stromal cells as the resultant proliferation of adherent MM cells.
The compound SU6668, an inhibitor of thyrosine kinase of VEGFR, is currently being investigated in a phase II MM study. 87 
Concluding remarks
The expression levels of VEGF, as well as MVD, as indicators of angiogenesis are accepted parameters in hematological tumors and correlated with the clinical outcome.
The importance of angiogenesis in MM is unquestionable, as well as the central role played by VEGF in survival, proliferation and diffusion of plasma cells with paracrine and autocrine mechanisms. Employment of an antibody against VEGF and small molecule tyrosine kinase inhibitors to interfere with its signaling illustrates the potential of antiangiogenic approaches in the treatment of MM. Nevertheless, several questions are still unsolved. Treatment directed against VEGF-A for example is effective, but only initially. Tumors eventually escape from inhibition by muting to express other angiogenic growth factors. 88 funds, Interuniversity Funds for Basic Research (FIRB), Rome, Italy). RR is the recipient of a fellowship from the European Union x94/342/CE.
